A Phase III Double Blind Randomized Placebo Controlled Study of Trastuzumab as Short Duration Preoperative Therapy in Patients With HER2-neu Positive Operable Breast Cancer
Phase of Trial: Phase III
Latest Information Update: 03 Jul 2019
Price : $35 *
At a glance
- Drugs Trastuzumab (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 24 Apr 2018 Planned primary completion date changed from 1 Feb 2018 to 1 Apr 2020.
- 01 Aug 2013 Actual initiation date changed from Feb 2013 to May 2013 as reported by ClinicalTrials.gov.